Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients

Pediatric Transplantation

Volumn 11, Issue 1, 2007, Pages 77-81

  Valentini, Rudolph P ^a   Nehlsen Cannarella, Sandra L ^a   Gruber, Scott A ^a   Mattoo, Tej K ^a   West, Miguel S ^a   Lang, Cheryl ^a   Imam, Abubakr A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crossmatch; HLAMatchmaker; Human leukocyte antigen; Intravenous immunoglobulin; Kidney transplantation; Panel reactive antibody; Pediatrics

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; DIPHENHYDRAMINE; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; POLYGRAM; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ALLELE; ARTICLE; CASE REPORT; COMPUTER PROGRAM; CYTOMEGALOVIRUS INFECTION; DESENSITIZATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; HIGH RISK POPULATION; HLA MATCHING; HLA TYPING; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; OPTIMAL DRUG DOSE; PEDIATRIC SURGERY; SCHOOL CHILD; TREATMENT OUTCOME;

ANTIBODIES; CHILD; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNIZATION; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; REOPERATION; SOFTWARE; TRANSPLANTATION, HOMOLOGOUS;

EID: 33846252768     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00617.x     Document Type: Article

References (25)

1. JORDAN SC, TYAN D, STABLEIN D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004: 15: 3256-3262.
2. DUQUESNOY RJ. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. I. Description of the Algorithm. Hum Immunol 2002: 63: 339-352.
3. DUQUESNOY RJ, TAKEMOTO S, DE LANGE P, et al. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino-acid triplet level on kidney transplant survival. Transplantation 2003: 75: 884-889.
4. BOHRINGER D, REINHARD T, DUQUESNOY RJ, et al. Beneficial effect of matching at the HLA-A and B amino-acid triplet level on rejection free survival in penetrating keratoplasty. Transplantation 2004: 77: 417-421.
5. LAUX G, MYTLINEOS J, OPELZ G. Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplantation. Transplantation 2004: 77: 902-907.
6. DUQUESNOY R, CLAAS F. Is the application of Hlamatchmaker relevant in kidney transplantation? Transplantation 2005: 79: 250-251.
7. LOBASHEVSKY AL, SENKBEIL RW, SHOAF JL, et al. The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in high PRA renal patients. Hum Immunol 2002: 63: 364-374.
8. DUQUESNOY RJ, WITYLIET M, DOXIADIS II, DE FIJTER H, CLAAS FH. HLAMatchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates. Transpl Int 2004: 17: 22-30.
9. CLAAS FH, WITYLIET MD, DUQUESNOY RJ, PERSIJN GG, DOXIADIS II. The acceptable mismatch program as a fast tool to transplant highly sensitized patients awaiting a post-mortal kidney: Short waiting time and excellent graft outcome. Transplantation 2004: 78: 190-193.
10. HARIRIAN A, FAGOAGA O, DANESHVAR H, et al. Predictive value of human leucocyte antigen epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort. Clin Transplant 2006: 20: 226-233.
11. JORDAN SC, VO A, BUNNAPRADIST S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in livingdonor and cadaver recipients. Transplantation 2003: 76: 631-636.
12. DALAKAS MC. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology 1994: 44: 223-226.
13. GLOTZ D, ANTOINE C, JULIA P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002: 2: 758-760.
14. GOTTLIEB S. Intravenous immunoglobulin increases risk of thrombotic events. BMJ 2002: 324: 1056.
15. DUQUESNOY RJ, HOWE J, TAKEMOTO S. HLAmatchmaker: A molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients. Transplantation 2003: 75: 889-897.
16. CLAAS FH, DANKERS MK, OUDSHOORN M, et al. Differential immunogenicity of HLA mismatches in clinical transplantation. Transpl Immunol 2005: 14: 187-191.
17. DOXIADIS II, DUQUESNOY RJ, CLAAS FH. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 2005: 17: 536-540.
18. TAUBE DH, WILLIAMS DG, CAMERON JS, et al. Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet 1984: 1: 824-828.
19. PALMER A, TAUBE D, WELSH K, BEWICK M, GJORSTRUP P, THICK M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989: 1: 10-12.
20. HIGGINS RM, BEVAN DJ, CAREY BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996: 348: 1208-1211.
21. GLOTZ D, HAYMANN JP, SANSONETTI N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993: 56: 335-337.
22. MONTGOMERY RA, ZACHARY AA, RACUSEN LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000: 70: 887-895.
23. TYAN DB, LI VA, CZER L, TRENTO A, JORDAN SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994: 57: 553-562.
24. AL-UZRI AY, SELTZ B, YORGIN PD, SPIER CM, ANDREONI K. Successful renal transplant outcome after intravenous gammaglobulin treatment of a highly sensitized pediatric recipient. Pediatr Transplant 2002: 6: 161-165.
25. TAKEMOTO S, PORT FK, CLAAS FH, DUQUESNOY RJ. HLA matching for kidney transplantation. Hum Immunol 2004: 65: 1489-1505.